医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EdiGENE Raises $15 Million in Series B Funding

2019年04月10日 PM02:16
このエントリーをはてなブックマークに追加


 

TOKYO & CAMBRIDGE, Mass.

EdiGENE, an emerging biotechnology company developing new CRISPR based therapies for treatment of genetic disorders, announced today that it has raised 1.6 Billion-yen (approx. $15 Million) as the first tranche of Series B round.

Participants in the Series B included new investors, UTokyo Innovation Platform along with continued support of existing investors, including SBI Investment, Fast Track Initiative, SMBC Venture Capital, Mizuho Capital, CareNet Group.

A subset of genetic diseases is caused by mutations in the coding region that result in production of proteins which malfunction or function less well. Canonical gene editing, removal and replacement of the gene can correct these. On the other hand, another fraction of genetic disorders is caused by loss of regulation – resulting in excess or insufficient protein production – and include more than 660 genes that are currently estimated to cause human disease due to haploinsufficiency. EdiGENE’s unique technology platform, CRISPR-GNDM (Guide Nucleotide Directed Modulation), is capable of normalizing levels of gene expression without cutting the DNA or RNA. By altering epigenetics to control levels of gene, and consequently protein expression, EdiGENE’s novel approach to gene modulation has the potential to prevent, modify and cure a wide range of genetic diseases to improve patients’ lives.

“Epigenetics acts like a ‘switch’ of gene function and altering gene expression is a unique way to treat genetic disorders. It has huge potential to cure patients affected by these genetic disorders,” said Haru Morita, Chief Executive Officer of EdiGENE. “Since the founding of EdiGENE in 2016, we have made remarkable progress in developing CRISPR-GNDM as a new therapeutic modality for precision gene therapy. We are excited to have the support from this group of investors to help us achieve our mission.”

EdiGENE plans to use the proceeds of the financing to advance the groundbreaking science forward, extend its leadership position in gene modulation technology, and progress pipeline programs towards the clinic where they will impact patients suffering from serious genetic diseases.

About EdiGENE

EdiGENE is an emerging biotech company that develops therapeutics using its proprietary technology CRISPR-GNDM. Our people, products, and partners believe “every life deserves attention” and our mission is to develop therapeutics primarily for genetic orphan disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190409006067/en/

CONTACT

EdiGENE Corporation
Sawako Nakamura
media@edi-gene.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 2019年台湾医疗科技展展商简介
  • Alpha Holdings Comments on OncoSec’s Inability to Defend China Grand Takeover
  • Sensor Electronic Technology Obtains Permanent Injunction Against U.S. UV LED Companies
  • LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
  • AJC Organized the ASEAN Services Trade Forum in Tokyo to Discuss the Emerging Demands for Health and Social Services in ASEAN and Its Investment Opportunities